[1]邓玮玮,张春银.放射性核素显像在帕金森病鉴别诊断中的应用[J].国际放射医学核医学杂志,2017,41(2):132-136.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
 Deng Weiwei,Zhang Chunyin.Application of radionuclide imaging on differential diagnosis of Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):132-136.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
点击复制

放射性核素显像在帕金森病鉴别诊断中的应用(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第2期
页码:
132-136
栏目:
综述
出版日期:
2017-03-25

文章信息/Info

Title:
Application of radionuclide imaging on differential diagnosis of Parkinson disease
作者:
邓玮玮 张春银
646000 泸州, 西南医科大学附属医院核医学科
Author(s):
Deng Weiwei Zhang Chunyin
Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
关键词:
帕金森病放射性核素显像诊断鉴别
Keywords:
Parkinson diseaseRadionuclide imagingDiagnosis differential
DOI:
10.3760/cma.j.issn.1673-4114.2017.02.010
摘要:
帕金森病(PD)的鉴别诊断在临床上是一大难题,放射性核素显像能够为PD的鉴别诊断提供分子水平和代谢水平的信息,有助于PD与非典型帕金森综合征和特发性震颤(ET)等疾病的鉴别。笔者就放射性核素显像在PD鉴别诊断中的应用做一综述。
Abstract:
The differential diagnosis of Parkinson disease can be challenging. Radionuclide imaging can provide the molecular and metabolic information so that it is helpful for differential diagnosis of Parkinson disease from atypical parkinsonism or other neurological disability such as essential tremor. The application of radionuclide imaging in the differential diagnosis of Parkinson disease was reviewed in this article.

参考文献/References:

[1] Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease:Clinicopathologic study[J]. Neurology, 2014, 83(5):406-412. DOI:10. 1212/WNL. 0000000000000641.
[2] Holtbernd F, Eidelberg D. The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes[J]. Semin Neurol, 2014, 34(2):202-209. DOI:10. 1055/s-0034-1381733.
[3] Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease[J]. Clin Med(Lond), 2016, 16(4):371-375. DOI:10.7861/clinmedicine. 16-4-371.
[4] Sarikaya I. PET imaging in neurology:Alzheimer’s and Parkinson’s diseases[J]. Nucl Med Commun, 2015, 36(8):775-781. DOI:10. 1097/mnm. 0000000000000320.
[5] Picco A, Morbelli S, Piccardo A, et al. Brain 18F-DOPA PET and cognition in de novo Parkinson’s disease[J]. Eur J Nucl Med Mol Imaging, 2015, 42(7):1062-1070. DOI:10. 1007/s00259-015-3039-0.
[6] Otsuka M, Ichiya Y, Hosokawa S, et al. Striatal blood flow, glucose metabolism and 18F-dopa uptake:difference in Parkinson’s disease and atypical parkinsonism[J]. J Neurol Neurosurg Psychiatry, 1991, 54(10):898-904. DOI:10. 1136/jnnp. 54. 10. 898.
[7] Calabria FF, Calabria E, Gangemi V, et al. Current status and future challenges of brain imaging with 18F-DOPA PET for movement disorders[J]. Hell J Nucl Med, 2016, 19(1):33-41. DOI:10. 1967/s002449910335.
[8] Jaimini A, Tripathi M, D’Souza MM, et al. Utility of intrastriatal ratios of FDOPA to differentiate idiopathic Parkinson’s disease from atypical parkinsonian disorders[J]. Nucl Med Commun, 2013, 34(5):426-431. DOI:10. 1097/MNM. 0b013e32835fcd7f.
[9] Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of[I-123] -FP-CIT SPECT imaging:the[I-123] -FP-CIT study group[J]. Mov Disord, 2000, 15(3):503-510.
[10] Vlaar AM, van Kroonenburgh MJ, Kessels AG, et al. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes[J]. BMC Neurol, 2007, 7:27. DOI:10. 1186/1471-2377-7-27.
[11] Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes[J]. Eur Neurol, 2008, 59(5):258-266. DOI:10. 1159/000115640.
[12] Lorberboym M, Treves TA, Melamed E, et al.[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease[J]. Mov Disord, 2006, 21(4):510-514. DOI:10. 1002/mds. 20748.
[13] Messa C, Volonté MA, Fazio F, et al. Differential distribution of striatal[123I]beta-CIT in Parkinson’s disease and progressive supranuclear palsy, evaluated with single-photon emission tomography[J]. Eur J Nucl Med, 1998, 25(9):1270-1276. DOI:10. 1007/s002590050295.
[14] Plotkin M, Amthauer H, Klaffke S, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes:study on 72 patients[J]. J Neural Transm(Vienna), 2005, 112(5):677-692. DOI:10. 1007/s00702-004-0208-x.
[15] Nocker M, Seppi K, Donnemiller E, et al. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy:a voxel-based analysis of[123I]β-CIT SPECT[J]. Eur J Nucl Med Mol Imaging, 2012, 39(6):1012-1020. DOI:10. 1007/s00259-012-2100-5.
[16] Brigo F, Matinella A, Erro R, et al.[123I]FP-CIT SPECT(DaTSCAN) may be a useful tool to differentiate between Parkinson’s disease and vascular or drug-induced parkinsonisms:a meta-analysis[J]. Eur J Neurol, 2014, 21(11):1369-1390. DOI:10. 1111/ene. 12444.
[17] Van Laere K, Clerinx K, D’hondt E, et al. Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease[J]. J Nucl Med, 2010, 51(4):588-595. DOI:10. 2967/jnumed. 109. 070144.
[18] Tatsch K, Schwarz J, Oertel WH, et al. SPECT imaging of dopamine D2 receptors with 123I-IBZM:initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease[J]. Nucl Med Commun, 1991, 12(8):699-707. DOI:10. 1097/00006231-199108000-00005.
[19] Südmeyer M, Antke C, Zizek T, et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism:a multidimensional statistical approach[J]. J Nucl Med, 2011, 52(5):733-740. DOI:10. 2967/jnumed. 110. 086959.
[20] Hellwig S, Amtage F, Kreft A, et al.[18F]FDG-PET is superior to[125I]IBZM-SPECT for the differential diagnosis of parkinsonism[J]. Neurology, 2012, 79(13):1314-1322. DOI:10. 1212/WNL. 0b013e31826c1b0a.
[21] Koch W, Hamann C, Radau PE, et al. Does combined imaging of the pre-and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?[J]. Eur J Nucl Med Mol Imaging, 2007, 34(8):1265-1273. DOI:10. 1007/s00259-007-0375-8.
[22] Ishibashi K, Nishina H, Ishiwata K, et al. Individual time course of pre-and postsynaptic PET imaging may improve differential diagnosis of Parkinson’s disease and multiple system atrophy:a case report[J]. BMC Res Notes, 2015, 8:496. DOI:10. 1186/s13104-015-1522-0.
[23] Juh R, Kim J, Moon D, et al. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET[J]. Eur J Radiol, 2004, 51(3):223-233. DOI:10. 1016/S0720-048X(03)00214-6.
[24] Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson’s disease with 18F-fluorodeoxyglucose and positron emission tomography[J]. Neurology, 1995, 45(11):1995-2004. DOI:10. 1212/WNL. 45. 11. 1995.
[25] Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism:a metabolic imaging study using pattern analysis[J]. Lancet Neurol, 2010, 9(2):149-158. DOI:10. 1016/S1474-4422(10)70002-8.
[26] Tripathi M, Tang CC, Feigin A, et al. Automated differential diagnosis of early parkinsonism using metabolic brain networks:a validation study[J]. J Nucl Med, 2016, 57(1):60-66. DOI:10. 2967/jnumed. 115. 161992.
[27] Orimo S, Suzuki M, Inaba A, et al. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism:a systematic review and meta-analysis[J]. Parkinsonism Relat Disord, 2012, 18(5):494-500. DOI:10. 1016/j. parkreldis. 2012. 01. 009.
[28] Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders[J]. Mov Disord, 2009, Suppl 2:S732-741. DOI:10. 1002/mds. 22499.
[29] Nagayama H, Hamamoto M, Ueda M, et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 2005, 76(2):249-251. DOI:10. 1136/jnnp. 2004. 037028.

相似文献/References:

[1]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
 Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
 Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
 Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
 Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[5]孙芳芳,张欣.uPAR放射性核素靶向显像研究进展[J].国际放射医学核医学杂志,2016,40(3):230.[doi:10.3760/cma.j.issn.1673-4114.2016.03.013]
 Sun Fangfang,Zhang Xin.Research progress of uPAR-targeted nuclear imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):230.[doi:10.3760/cma.j.issn.1673-4114.2016.03.013]
[6]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
 Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[7]安淑娴,宋少莉,黄钢.放射性核素标记的凋亡显像剂的研究进展[J].国际放射医学核医学杂志,2015,39(6):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
 An Shuxian,Song Shaoli,Huang Gang.Recent advances in apoptosis imaging using radionuclide-labeled tracers[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
[8]黄建敏,解朋,刘晓梅,等.以整合素αvβ3为靶点的肿瘤分子显像及靶向治疗[J].国际放射医学核医学杂志,2015,39(3):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
 Huang Jianmin,Xie Peng,Liu Xiaomei,et al.Integrins αvβ3 in molecular imaging and targeted therapy of neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
[9]郭宵峰,刘建中,孙琦婷.肺通气/灌注平面显像与肺灌注SPECT/CT对肺栓塞诊断价值的对比性研究[J].国际放射医学核医学杂志,2015,39(4):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
 Guo Xiaofeng,Liu Jianzhong,Sun Qiting.Comparative study of pulmonary ventilation/perfusion planar imaging and pulmonary perfusion SPECT combined with low-dose CT in the diagnosis of pulmonary embolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
[10]马春旭,袁卫红.甲状腺结节影像学诊断研究进展[J].国际放射医学核医学杂志,2014,38(1):48.[doi:10.3760/cma.j.issn 1673-4114.2014.01.010]
 Ma Chunxu,Yuan Weihong.Advanced research on imaging diagnosis of thyroid nodule[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):48.[doi:10.3760/cma.j.issn 1673-4114.2014.01.010]

备注/Memo

备注/Memo:
收稿日期:2017-02-24。
通讯作者:张春银,Email:zhangchunyin345@sina.com
更新日期/Last Update: 2017-04-24